vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Varex Imaging Corp (VREX). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($268.1M vs $209.6M, roughly 1.3× Varex Imaging Corp). ACADIA PHARMACEUTICALS INC runs the higher net margin — 1.4% vs 1.1%, a 0.3% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.7% vs 4.9%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (5.3% CAGR vs 0.8%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Varex Imaging Corp is a global supplier of advanced imaging components and solutions, including X-ray tubes, digital flat panel detectors, and image processing software. Its products serve medical imaging, radiation oncology, and industrial non-destructive testing segments, with customers across key global markets.
ACAD vs VREX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $268.1M | $209.6M |
| Net Profit | $3.6M | $2.3M |
| Gross Margin | — | 33.3% |
| Operating Margin | -1.7% | 7.3% |
| Net Margin | 1.4% | 1.1% |
| Revenue YoY | 9.7% | 4.9% |
| Net Profit YoY | — | 866.7% |
| EPS (diluted) | $0.02 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $268.1M | $209.6M | ||
| Q4 25 | $284.0M | $228.9M | ||
| Q3 25 | $278.6M | $203.0M | ||
| Q2 25 | $264.6M | $212.9M | ||
| Q1 25 | $244.3M | $199.8M | ||
| Q4 24 | $259.6M | — | ||
| Q3 24 | $250.4M | $205.7M | ||
| Q2 24 | $242.0M | $209.1M |
| Q1 26 | $3.6M | $2.3M | ||
| Q4 25 | $273.6M | $12.2M | ||
| Q3 25 | $71.8M | $-89.1M | ||
| Q2 25 | $26.7M | $6.9M | ||
| Q1 25 | $19.0M | $-300.0K | ||
| Q4 24 | $143.7M | — | ||
| Q3 24 | $32.8M | $-51.1M | ||
| Q2 24 | $33.4M | $1.4M |
| Q1 26 | — | 33.3% | ||
| Q4 25 | 90.8% | 34.0% | ||
| Q3 25 | 92.2% | 33.3% | ||
| Q2 25 | 92.2% | 36.0% | ||
| Q1 25 | 91.7% | 34.3% | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | 32.6% | ||
| Q2 24 | 92.5% | 32.0% |
| Q1 26 | -1.7% | 7.3% | ||
| Q4 25 | 6.1% | 8.6% | ||
| Q3 25 | 12.8% | -39.8% | ||
| Q2 25 | 12.2% | 10.4% | ||
| Q1 25 | 7.9% | 5.6% | ||
| Q4 24 | 59.1% | — | ||
| Q3 24 | 12.6% | 5.3% | ||
| Q2 24 | 12.6% | 4.4% |
| Q1 26 | 1.4% | 1.1% | ||
| Q4 25 | 96.3% | 5.3% | ||
| Q3 25 | 25.8% | -43.9% | ||
| Q2 25 | 10.1% | 3.2% | ||
| Q1 25 | 7.8% | -0.2% | ||
| Q4 24 | 55.4% | — | ||
| Q3 24 | 13.1% | -24.8% | ||
| Q2 24 | 13.8% | 0.7% |
| Q1 26 | $0.02 | $0.05 | ||
| Q4 25 | $1.61 | $0.29 | ||
| Q3 25 | $0.42 | $-2.15 | ||
| Q2 25 | $0.16 | $0.17 | ||
| Q1 25 | $0.11 | $-0.01 | ||
| Q4 24 | $0.86 | — | ||
| Q3 24 | $0.20 | $-1.25 | ||
| Q2 24 | $0.20 | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $125.6M |
| Total DebtLower is stronger | — | $367.6M |
| Stockholders' EquityBook value | — | $476.9M |
| Total Assets | $1.6B | $1.1B |
| Debt / EquityLower = less leverage | — | 0.77× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $125.6M | ||
| Q4 25 | $177.7M | $155.1M | ||
| Q3 25 | $258.0M | $152.6M | ||
| Q2 25 | $253.6M | $223.0M | ||
| Q1 25 | $217.7M | $212.6M | ||
| Q4 24 | $319.6M | — | ||
| Q3 24 | $155.1M | $200.5M | ||
| Q2 24 | $177.1M | $190.0M |
| Q1 26 | — | $367.6M | ||
| Q4 25 | — | $367.5M | ||
| Q3 25 | — | $367.5M | ||
| Q2 25 | — | $567.2M | ||
| Q1 25 | — | $567.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $443.4M | ||
| Q2 24 | — | $443.1M |
| Q1 26 | — | $476.9M | ||
| Q4 25 | $1.2B | $472.6M | ||
| Q3 25 | $917.3M | $455.3M | ||
| Q2 25 | $822.4M | $549.7M | ||
| Q1 25 | $765.2M | $540.2M | ||
| Q4 24 | $732.8M | — | ||
| Q3 24 | $577.2M | $529.1M | ||
| Q2 24 | $516.7M | $581.2M |
| Q1 26 | $1.6B | $1.1B | ||
| Q4 25 | $1.6B | $1.1B | ||
| Q3 25 | $1.3B | $1.1B | ||
| Q2 25 | $1.2B | $1.4B | ||
| Q1 25 | $1.1B | $1.3B | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $976.9M | $1.2B | ||
| Q2 24 | $914.1M | $1.3B |
| Q1 26 | — | 0.77× | ||
| Q4 25 | — | 0.78× | ||
| Q3 25 | — | 0.81× | ||
| Q2 25 | — | 1.03× | ||
| Q1 25 | — | 1.05× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.76× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-16.1M |
| Free Cash FlowOCF − Capex | — | $-26.8M |
| FCF MarginFCF / Revenue | — | -12.8% |
| Capex IntensityCapex / Revenue | — | 5.1% |
| Cash ConversionOCF / Net Profit | — | -7.00× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $-16.1M | ||
| Q4 25 | $-48.7M | $7.9M | ||
| Q3 25 | $74.3M | $7.7M | ||
| Q2 25 | $64.0M | $16.6M | ||
| Q1 25 | $20.3M | $9.5M | ||
| Q4 24 | $40.4M | — | ||
| Q3 24 | $63.2M | $25.9M | ||
| Q2 24 | $25.0M | $8.0M |
| Q1 26 | — | $-26.8M | ||
| Q4 25 | — | $2.3M | ||
| Q3 25 | $73.9M | $1.4M | ||
| Q2 25 | — | $9.8M | ||
| Q1 25 | — | $5.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | $63.2M | $19.9M | ||
| Q2 24 | — | $3.3M |
| Q1 26 | — | -12.8% | ||
| Q4 25 | — | 1.0% | ||
| Q3 25 | 26.5% | 0.7% | ||
| Q2 25 | — | 4.6% | ||
| Q1 25 | — | 2.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.2% | 9.7% | ||
| Q2 24 | — | 1.6% |
| Q1 26 | — | 5.1% | ||
| Q4 25 | — | 2.4% | ||
| Q3 25 | 0.1% | 3.1% | ||
| Q2 25 | — | 3.2% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | 2.9% | ||
| Q2 24 | — | 2.2% |
| Q1 26 | — | -7.00× | ||
| Q4 25 | -0.18× | 0.65× | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 2.40× | 2.41× | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | 5.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
Segment breakdown not available.
VREX
| Medical Segment | $144.8M | 69% |
| Industrial Segment | $64.8M | 31% |
